Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

By R. Gardner, O. Finney, Colleen Annesley, Hannah M Brakke, C. Summers, K. Leger, M. Bleakley, Christopher Brown, Stephanie Mgebroff, K. Kelly-Spratt and 7 more. Blood, 2017

1,016 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Oncology

View Paper: https://www.semanticscholar.org/paper/e6d2cbb36babc28fa68e8629bedba5703e34e0df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. J. Kochenderfer
2. Jennifer N. Brudno
3. R. Brentjens

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno
3. Michel Sadelain
4. R. Brentjens
5. I. Rivière

Citations in the corpus

• Mechanisms of resistance to CAR T cell therapy (2019, neutral): “Gardner et al.(8) 43 40 (93) 7 (18) ~3 11 of 40 subsequently underwent HSCT”
• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “However, in retrospective reviews, patients receiving corticosteroids for immunosuppression have had similar antimalignancy responses [25,57]; effects on long-term remission durability are undetermined.”
• Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018, result): “The rate of neurotoxicity observed in our study is comparable with other studies of CD19 CAR T cells incorporating either CD28 or 4-1BB costimulation (3, 4, 6).”